nodes	percent_of_prediction	percent_of_DWPC	metapath
Almotriptan—MAOA—Clearance of dopamine—SLC6A3—Gilles de la Tourette syndrome	0.121	0.147	CbGpPWpGaD
Almotriptan—MAOA—Biogenic Amine Synthesis—HDC—Gilles de la Tourette syndrome	0.0962	0.116	CbGpPWpGaD
Almotriptan—MAOA—Neurotransmitter Clearance In The Synaptic Cleft—SLC6A3—Gilles de la Tourette syndrome	0.0554	0.0669	CbGpPWpGaD
Almotriptan—Sumatriptan—DRD2—Gilles de la Tourette syndrome	0.0329	1	CrCbGaD
Almotriptan—HTR1D—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.0314	0.038	CbGpPWpGaD
Almotriptan—HTR1B—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.0307	0.0372	CbGpPWpGaD
Almotriptan—HTR1D—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0259	0.0313	CbGpPWpGaD
Almotriptan—HTR1B—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0253	0.0306	CbGpPWpGaD
Almotriptan—HTR1D—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0221	0.0267	CbGpPWpGaD
Almotriptan—HTR1B—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0216	0.0261	CbGpPWpGaD
Almotriptan—HTR1D—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0214	0.0259	CbGpPWpGaD
Almotriptan—HTR1B—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.021	0.0254	CbGpPWpGaD
Almotriptan—HTR1D—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.02	0.0241	CbGpPWpGaD
Almotriptan—HTR1B—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0195	0.0236	CbGpPWpGaD
Almotriptan—HTR1D—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0185	0.0224	CbGpPWpGaD
Almotriptan—HTR1B—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0182	0.022	CbGpPWpGaD
Almotriptan—HTR1D—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.018	0.0218	CbGpPWpGaD
Almotriptan—HTR1B—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0176	0.0213	CbGpPWpGaD
Almotriptan—HTR1D—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0168	0.0203	CbGpPWpGaD
Almotriptan—HTR1B—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0164	0.0199	CbGpPWpGaD
Almotriptan—HTR1D—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.014	0.0169	CbGpPWpGaD
Almotriptan—HTR1B—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0137	0.0165	CbGpPWpGaD
Almotriptan—FMO3—nervous system—Gilles de la Tourette syndrome	0.0123	0.0879	CbGeAlD
Almotriptan—FMO3—central nervous system—Gilles de la Tourette syndrome	0.0118	0.0846	CbGeAlD
Almotriptan—HTR1D—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0117	0.0142	CbGpPWpGaD
Almotriptan—HTR1B—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0115	0.0139	CbGpPWpGaD
Almotriptan—FMO3—brain—Gilles de la Tourette syndrome	0.0094	0.0672	CbGeAlD
Almotriptan—HTR1B—midbrain—Gilles de la Tourette syndrome	0.00878	0.0627	CbGeAlD
Almotriptan—HTR1D—midbrain—Gilles de la Tourette syndrome	0.0085	0.0607	CbGeAlD
Almotriptan—FMO3—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00741	0.00895	CbGpPWpGaD
Almotriptan—HTR1B—nervous system—Gilles de la Tourette syndrome	0.00722	0.0516	CbGeAlD
Almotriptan—HTR1D—nervous system—Gilles de la Tourette syndrome	0.00699	0.0499	CbGeAlD
Almotriptan—HTR1B—central nervous system—Gilles de la Tourette syndrome	0.00695	0.0496	CbGeAlD
Almotriptan—HTR1D—central nervous system—Gilles de la Tourette syndrome	0.00673	0.0481	CbGeAlD
Almotriptan—MAOA—midbrain—Gilles de la Tourette syndrome	0.00647	0.0462	CbGeAlD
Almotriptan—HTR1B—brain—Gilles de la Tourette syndrome	0.00552	0.0394	CbGeAlD
Almotriptan—HTR1D—brain—Gilles de la Tourette syndrome	0.00534	0.0381	CbGeAlD
Almotriptan—MAOA—nervous system—Gilles de la Tourette syndrome	0.00532	0.038	CbGeAlD
Almotriptan—MAOA—central nervous system—Gilles de la Tourette syndrome	0.00512	0.0366	CbGeAlD
Almotriptan—FMO3—Metabolism—HDC—Gilles de la Tourette syndrome	0.00489	0.00591	CbGpPWpGaD
Almotriptan—HTR1D—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00459	0.00555	CbGpPWpGaD
Almotriptan—HTR1B—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00449	0.00543	CbGpPWpGaD
Almotriptan—HTR1D—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00445	0.00539	CbGpPWpGaD
Almotriptan—HTR1B—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00436	0.00527	CbGpPWpGaD
Almotriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00426	0.00515	CbGpPWpGaD
Almotriptan—MAOA—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.00422	0.0051	CbGpPWpGaD
Almotriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00417	0.00504	CbGpPWpGaD
Almotriptan—HTR1D—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00415	0.00502	CbGpPWpGaD
Almotriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00413	0.005	CbGpPWpGaD
Almotriptan—MAOA—brain—Gilles de la Tourette syndrome	0.00407	0.029	CbGeAlD
Almotriptan—HTR1B—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00406	0.00491	CbGpPWpGaD
Almotriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00405	0.00489	CbGpPWpGaD
Almotriptan—CYP2E1—nervous system—Gilles de la Tourette syndrome	0.00399	0.0285	CbGeAlD
Almotriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00385	0.00466	CbGpPWpGaD
Almotriptan—CYP2E1—central nervous system—Gilles de la Tourette syndrome	0.00384	0.0275	CbGeAlD
Almotriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00377	0.00456	CbGpPWpGaD
Almotriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00365	0.00441	CbGpPWpGaD
Almotriptan—CYP2C8—brain—Gilles de la Tourette syndrome	0.00363	0.0259	CbGeAlD
Almotriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00357	0.00432	CbGpPWpGaD
Almotriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00354	0.00428	CbGpPWpGaD
Almotriptan—MAOA—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00354	0.00428	CbGpPWpGaD
Almotriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00347	0.00419	CbGpPWpGaD
Almotriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.0033	0.00399	CbGpPWpGaD
Almotriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00323	0.00391	CbGpPWpGaD
Almotriptan—MAOA—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.00323	0.0039	CbGpPWpGaD
Almotriptan—CYP3A4—nervous system—Gilles de la Tourette syndrome	0.00321	0.023	CbGeAlD
Almotriptan—CYP2D6—nervous system—Gilles de la Tourette syndrome	0.00316	0.0226	CbGeAlD
Almotriptan—CYP3A4—central nervous system—Gilles de la Tourette syndrome	0.00309	0.0221	CbGeAlD
Almotriptan—CYP2E1—brain—Gilles de la Tourette syndrome	0.00305	0.0218	CbGeAlD
Almotriptan—CYP2D6—central nervous system—Gilles de la Tourette syndrome	0.00304	0.0217	CbGeAlD
Almotriptan—HTR1D—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00278	0.00336	CbGpPWpGaD
Almotriptan—HTR1B—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00272	0.00329	CbGpPWpGaD
Almotriptan—HTR1D—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.0027	0.00326	CbGpPWpGaD
Almotriptan—HTR1D—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.0027	0.00326	CbGpPWpGaD
Almotriptan—HTR1B—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00264	0.00319	CbGpPWpGaD
Almotriptan—HTR1B—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00264	0.00319	CbGpPWpGaD
Almotriptan—HTR1D—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00251	0.00304	CbGpPWpGaD
Almotriptan—HTR1B—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00246	0.00297	CbGpPWpGaD
Almotriptan—CYP2D6—brain—Gilles de la Tourette syndrome	0.00242	0.0173	CbGeAlD
Almotriptan—MAOA—Metabolism—HDC—Gilles de la Tourette syndrome	0.00234	0.00283	CbGpPWpGaD
Almotriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00231	0.00279	CbGpPWpGaD
Almotriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00226	0.00274	CbGpPWpGaD
Almotriptan—HTR1D—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00176	0.00213	CbGpPWpGaD
Almotriptan—HTR1B—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00172	0.00208	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00157	0.0019	CbGpPWpGaD
Almotriptan—HTR1B—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00154	0.00186	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00152	0.00184	CbGpPWpGaD
Almotriptan—HTR1B—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00149	0.0018	CbGpPWpGaD
Almotriptan—CYP2E1—Metabolism—HDC—Gilles de la Tourette syndrome	0.00143	0.00173	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00143	0.00172	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00142	0.00172	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.0014	0.00169	CbGpPWpGaD
Almotriptan—HTR1B—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00139	0.00168	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00138	0.00167	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00136	0.00164	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00129	0.00156	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00126	0.00153	CbGpPWpGaD
Almotriptan—CYP2C8—Metabolism—HDC—Gilles de la Tourette syndrome	0.00124	0.0015	CbGpPWpGaD
Almotriptan—CYP2C19—Metabolism—HDC—Gilles de la Tourette syndrome	0.00111	0.00134	CbGpPWpGaD
Almotriptan—CYP2D6—Metabolism—HDC—Gilles de la Tourette syndrome	0.00102	0.00123	CbGpPWpGaD
Almotriptan—HTR1D—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000994	0.0012	CbGpPWpGaD
Almotriptan—HTR1B—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000974	0.00118	CbGpPWpGaD
Almotriptan—HTR1D—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000903	0.00109	CbGpPWpGaD
Almotriptan—HTR1B—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000884	0.00107	CbGpPWpGaD
Almotriptan—CYP1A2—Metabolism—HDC—Gilles de la Tourette syndrome	0.000862	0.00104	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000842	0.00102	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000825	0.000997	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000818	0.000988	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000801	0.000968	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000762	0.000921	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000746	0.000902	CbGpPWpGaD
Almotriptan—CYP3A4—Metabolism—HDC—Gilles de la Tourette syndrome	0.000665	0.000804	CbGpPWpGaD
Almotriptan—HTR1D—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000533	0.000645	CbGpPWpGaD
Almotriptan—HTR1B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000522	0.000632	CbGpPWpGaD
